Severe renal impairment
(eGFR <30 mL/min/
1.73 m2):§
25 mg OD
Dosing
Explore Trajenta® for use as monotherapy in patients for whom metformin is inappropriate due to contraindications or intolerance2
Please see the Trajenta® Product Monograph for complete dosing and administration information.
No dose adjustment required for patients with renal impairment. Use with caution in patients with ESRD and those on dialysis.
No dose adjustment required for patients with mild and moderate hepatic impairment. Not recommended in patients with severe hepatic impairment.
No dose adjustment required based on BMI.
No dose adjustment required based on race. Race had no obvious effect on the plasma concentrations of linagliptin based on a composite analysis of available pharmacokinetic data.
No dose adjustment required for patients with renal impairment
Use with caution in patients with ESRD and those on dialysis.1
Trajenta® can be used with basal insulin
A lower dose of insulin may be considered to reduce the risk of hypoglycemia.
Sitagliptin | Saxagliptin | Trajenta® | |
---|---|---|---|
Dosage forms |
![]() 25 mg tablet
![]() 50 mg tablet
![]() 100 mg tablet
|
![]() 2.5 mg tablet
![]() 5 mg tablet
|
![]() 5 mg tablet
|
Recommended dose | 100 mg OD‡ | 5 mg OD | 5 mg OD |
Patients with renal impairment |
Mild to moderate renal impairment (eGFR ≥45 to no dose adjustment required Moderate renal impairment (eGFR ≥30 to 50 mg OD Severe renal impairment (eGFR <30 mL/min/ 25 mg OD |
Mild to moderate renal impairment (eGFR ≥45 to no dose adjustment required Moderate renal impairment (eGFR <45 mL/min/ 2.5 mg OD¶ |
No dose adjustment required |
Patients with ESRD | 25 mg OD without regard to the timing of dialysis for patients requiring hemodialysis or peritoneal dialysis§ | Not recommended for patients with ESRD requiring hemodialysis§ | Use with caution in patients with ESRD and those on dialysis |
Patients with hepatic impairment |
Mild to moderate hepatic impairment: no dose adjustment required Severe hepatic impairment: not recommended |
Moderate to severe hepatic impairment: not recommended |
Mild and moderate hepatic impairment: no dose adjustment required Severe hepatic impairment: not recommended |
Geriatrics (≥65 years of age) |
No dose adjustment necessary | No dose adjustment necessary | No dose adjustment necessary |
Pediatrics (<18 years of age) |
Not recommended | Should not be used | Should not be used |
Sitagliptin | Saxagliptin | Trajenta® |
---|---|---|
![]() 25 mg tablet
![]() 50 mg tablet
![]() 100 mg tablet
|
![]() 2.5 mg tablet
![]() 5 mg tablet
|
![]() 5 mg tablet
|
Sitagliptin | Saxagliptin | Trajenta® |
---|---|---|
100 mg OD‡ | 5 mg OD | 5 mg OD |
Sitagliptin | Saxagliptin | Trajenta® |
---|---|---|
Mild to moderate renal impairment (eGFR ≥45 to no dose adjustment required Moderate renal impairment (eGFR ≥30 to 50 mg OD Severe renal impairment (eGFR <30 mL/min/ 25 mg OD |
Mild to moderate renal impairment (eGFR ≥45 to no dose adjustment required Moderate renal impairment (eGFR <45 mL/min/ 2.5 mg OD¶ |
No dose adjustment required |
Sitagliptin | Saxagliptin | Trajenta® |
---|---|---|
25 mg OD without regard to the timing of dialysis for patients requiring hemodialysis or peritoneal dialysis§ | Not recommended for patients with ESRD requiring hemodialysis§ | Use with caution in patients with ESRD and those on dialysis |
Sitagliptin | Saxagliptin | Trajenta® |
---|---|---|
Mild to moderate hepatic impairment: no dose adjustment required Severe hepatic impairment: not recommended |
Moderate to severe hepatic impairment: not recommended |
Mild and moderate hepatic impairment: no dose adjustment required Severe hepatic impairment: not recommended |
Sitagliptin | Saxagliptin | Trajenta® |
---|---|---|
No dose adjustment necessary | No dose adjustment necessary | No dose adjustment necessary |
Sitagliptin | Saxagliptin | Trajenta® |
---|---|---|
Not recommended | Should not be used | Should not be used |
Comparative clinical significance has not been established.
Please see the respective Product Monographs for complete dosing and administration information.
As monotherapy or as combination therapy with metformin, with metformin and a sulfonylurea, with insulin (with or without metformin), or with pioglitazone (with or without metformin). When sitagliptin is used in combination with metformin and a sulfonylurea or with insulin (with or without metformin), a lower dose of insulin secretagogue or insulin may be considered to reduce the risk of hypoglycemia.
Because dosage adjustment is based on renal function, assess renal function prior to initiation of treatment and periodically thereafter.
Saxagliptin should be used with caution in patients with severe renal impairment (eGFR <30 mL/min/1.73 m2).